N–glycan Biopharmaceutical Reference Library
July 07, 2014
Thirty percent of approved drugs will be based on recombinant monoclonal antibody (rMab) drugs over the next 10 years. Glycosylation, the convalent addition of carbohydrates to proteins, can influence properties of rMab drugs and has to be closely monitored during drug development and production. Scientists from the University of California (California, USA) have developed a new liquid chromatography–mass spectrometry (LC–MS) N-glycan library based on eight commercially available recombinant monoclonal antibodies, for the rapid identification of glycosylated structures.